{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:48:09Z","timestamp":1790200089100,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders anatomically classified by distribution (unicentric CD [UCD], oligocentric CD [oligoCD], or multicentric CD [MCD]). Human herpes virus 8\u2013negative MCD is called idiopathic MCD (iMCD), which includes clinical subtypes with varying phenotypes and responses: TAFRO (thrombocytopenia, anasarca, fever, renal dysfunction and\/or reticulin fibrosis, and organomegaly), IPL (idiopathic plasmacytic lymphadenopathy), and not otherwise specified. OligoCD has recently emerged as an intermediate form between UCD and MCD, with unclear clinical behavior, and IPL has not been validated in a Western cohort. We retrospectively analyzed 217 patients with CD evaluated at our institution between January 2004 and August 2024. Survival probabilities were compared using log-rank tests. Overall, 57% had UCD, 20% had oligoCD, and 23% had iMCD. Patients with oligoCD and iMCD more frequently exhibited systemic symptoms than those with UCD. Patients with oligoCD and iMCD had significantly shorter event-free survival (EFS) of 8.9 and 2.3 years, respectively, than those with UCD (not reached; P&amp;lt; .001 and P&amp;lt; .02). Among iMCD subtypes, iMCD-IPL demonstrated a longer EFS than iMCD-TAFRO (P = .02), with no deaths during the follow-up periods. The results validate oligoCD and iMCD-IPL as new subtypes in this Western cohort. The survival outcome in oligoCD was intermediate between UCD and iMCD, with only a subset of patients with oligoCD requiring systemic therapy. iMCD-IPL had a favorable survival outcome in this US cohort, similar to what has been reported in non-Western countries. Tailoring treatment strategies to disease subtypes and vigilant monitoring of oligoCD for progression may improve survival outcomes in CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018324","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:57:34Z","timestamp":1766591854000},"page":"1487-1496","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study"],"prefix":"10.1182","volume":"10","author":[{"given":"Yoshito","family":"Nishimura","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Habermann","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Porrata","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Johnston","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas","family":"Witzig","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison C.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Phoenix, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Mayo Clinic Jacksonville, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-094X","authenticated-orcid":false,"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Mayo Clinic Jacksonville, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"16","key":"2026030916214854300_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2026030916214854300_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.2023023716","article-title":"Insights into the etiology of Castleman disease","volume":"143","author":"van Rhee","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026030916214854300_bib3","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/bloodadvances.2024014391","article-title":"Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry","volume":"9","author":"Pierson","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"2026030916214854300_bib4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2026030916214854300_bib5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2026030916214854300_bib6","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival","volume":"204","author":"Gao","year":"2024","journal-title":"Br J Haematol"},{"issue":"18","key":"2026030916214854300_bib7","doi-asserted-by":"crossref","first-page":"10301","DOI":"10.3390\/ijms231810301","article-title":"Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease","volume":"23","author":"Nishikori","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026030916214854300_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/jcp-2023-209280","article-title":"Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): factors to differentiate from IgG4-related disease","volume":"79","author":"Nishikori","year":"2025","journal-title":"J Clin Pathol"},{"issue":"11","key":"2026030916214854300_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman's disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"issue":"5","key":"2026030916214854300_bib10","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival","volume":"204","author":"Gao","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"2026030916214854300_bib11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.27612","article-title":"Exploring the clinical diversity of Castleman disease and TAFRO syndrome: a Japanese multicenter study on lymph node distribution patterns","volume":"100","author":"Otsuka","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"2026030916214854300_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.27507","article-title":"Cryoablation for unresectable unicentric Castleman disease","volume":"100","author":"Nishimura","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"2026030916214854300_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1440-1843.2008.01397.x","article-title":"Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome","volume":"14","author":"Maldonado","year":"2009","journal-title":"Respirology"},{"key":"2026030916214854300_bib14","first-page":"100720","article-title":"A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria","volume":"34","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"2026030916214854300_bib15","doi-asserted-by":"crossref","first-page":"974770","DOI":"10.3389\/fonc.2022.974770","article-title":"Long-term treatment outcome of Castleman's disease: a real-world experience","volume":"12","author":"Min","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2026030916214854300_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/106689690401200104","article-title":"Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia: a report of 16 cases","volume":"12","author":"Kojima","year":"2004","journal-title":"Int J Surg Pathol"},{"issue":"2","key":"2026030916214854300_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3960\/jslrt.22011","article-title":"Idiopathic plasmacytic lymphadenopathy: a conceptual history along with a translation of the original Japanese article published in 1980","volume":"62","author":"Takeuchi","year":"2022","journal-title":"J Clin Exp Hematop"},{"issue":"9","key":"2026030916214854300_bib18","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/ajh.27743","article-title":"International consensus histopathological criteria for subtyping idiopathic multicentric Castleman disease based on machine learning analysis","volume":"100","author":"Nishimura","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"2026030916214854300_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/bjh.15588","article-title":"Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data","volume":"184","author":"Morra","year":"2019","journal-title":"Br J Haematol"},{"issue":"21","key":"2026030916214854300_bib20","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1182\/bloodadvances.2023010745","article-title":"Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes","volume":"7","author":"Pierson","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2026030916214854300_bib21","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee","year":"2020","journal-title":"Blood Adv"},{"issue":"30","key":"2026030916214854300_bib22","doi-asserted-by":"crossref","first-page":"30408","DOI":"10.18632\/oncotarget.4655","article-title":"A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"6","author":"van Rhee","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"2026030916214854300_bib23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00277-018-3347-0","article-title":"Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease","volume":"97","author":"Dong","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"2026030916214854300_bib24","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman's disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"issue":"17","key":"2026030916214854300_bib25","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/bloodadvances.2020004016","article-title":"Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease","volume":"5","author":"Pierson","year":"2021","journal-title":"Blood Adv"},{"issue":"19","key":"2026030916214854300_bib26","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood.2019002792","article-title":"Increased mTOR activation in idiopathic multicentric Castleman disease","volume":"135","author":"Arenas","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026030916214854300_bib27","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1038\/s41467-022-34873-7","article-title":"CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease","volume":"13","author":"Pierson","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"2026030916214854300_bib28","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2019","journal-title":"J Clin Invest"},{"issue":"6","key":"2026030916214854300_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMc2412494","article-title":"Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman's Disease","volume":"392","author":"Mumau","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1487\/2505482\/blooda_adv-2025-018324-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1487\/2505482\/blooda_adv-2025-018324-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:21:56Z","timestamp":1773087716000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1487\/557473\/Comprehensive-analysis-of-subtype-specific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018324","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,25]]}}}